Across 47 Phase II/III endometrial or uterine cancer trial records, activity is concentrated in a recurring set of specialist oncology hubs. Hospital Universitari Vall d’Hebron leads with 21 of 1,033 normalized site listings, or 2.0%, while Spain holds 1,668 of 6,913 planned participants, or 24.1%. The strongest operational signal is a Spanish- and French-led hub network reused across Phase II and Phase III programs.
The top 10 sites account for 149 of 1,033 named site listings, or 14.4% of all listed site entries. Vall d’Hebron alone contributes 21 of 1,033 listings, or 2.0%, followed by Institut Gustave Roussy at 18 of 1,033, or 1.7%.
The site landscape is led by a compact cluster of repeat oncology hubs rather than a single dominant institution. Spain and France supply most of the highest-frequency names, reinforcing their central role in EU gynecologic oncology site strategy.
Phase II contributes 29 of 47 trials, or 61.7%, and 3,825 of 6,913 planned participants, or 55.3%. Phase III contributes 18 of 47 trials, or 38.3%, but 576 of 1,033 named site listings, or 55.8%, indicating broader site deployment in later-stage programs.
Phase II is trial-rich, but Phase III is more operationally distributed across named sites. That pattern is consistent with confirmatory studies expanding beyond the narrower site sets used in earlier-stage development.
Spain accounts for 1,668 of 6,913 planned participants, or 24.1%, while all other countries combined account for 5,245 of 6,913, or 75.9%. Spain therefore contributes nearly one in four planned participants across the full Phase II/III cohort.
Spain is not only overrepresented among top sites; it also carries the clearest enrollment-weight signal. For competitive site strategy, Spanish relationships appear disproportionately important in this disease segment.
All 47 of 47 analyzed records are oncology-linked, and at least 14 adjacent oncology disease categories appear alongside endometrial or uterine cancer labels. The most visible adjacencies include ovarian or peritoneal cancers, cervical or vulvar cancers, breast cancer, lung cancer, colorectal cancer, and broad solid-tumor programs.
Endometrial cancer site selection frequently appears embedded in multi-indication oncology development rather than operating as a fully isolated disease track. That broad overlap helps explain why the same large oncology hubs recur so often.
CTIS: Clinical Trials Information System.
Named site listing: one normalized occurrence of a listed clinical trial site in a trial geography record.
MMRd / MSI-H: mismatch repair deficient / microsatellite instability-high.
IRCCS: Istituto di Ricovero e Cura a Carattere Scientifico, an Italian research hospital designation.
GEJ: gastroesophageal junction.